High-efficient Neoantigen In Vitro Evaluation Platform
Creative Biolabs also tops the field of personalized cancer vaccines. We took the lead in seizing the potential advantages of the AI algorithm in predicting tumor neoantigens, and actively hatched them, so that we successfully launched an algorithm with world-class prediction accuracy. Based on this, we have developed a matching neoantigen in vitro evaluation platform to further verify the prediction results and provide a solid support for the development of personalized neoantigen cancer vaccines.
Neoantigen In Vitro Evaluation Platform - Accelerating the Development of Personalized Neoantigen Cancer Vaccines
The development of individualized cancer vaccines includes patient tumor tissue sampling, gene sequencing, mutation analysis, predictive analysis and selection of neoantigen, vaccine design, preparation and evaluation, and clinical administration of vaccines. The most critical core of this personalized tumor vaccine strategy is the prediction of neoantigen that is exclusively present in cancer cells and has immunogenicity, because the factors that affect gene mutation and make it neoantigen include whether it is non-synonymous mutations, whether the mutation is expressed, whether the mutated gene can be cut, whether the expressed mutant protein can bind to HLA molecules, etc., so not all mutations can become neoantigen or be made into vaccines. Therefore, accurate prediction of neoantigen is the first and most critical step in the development of personalized cancer vaccines. In this regard, Creative Biolabs has launched the highly acclaimed AI-aided analysis platform.
Creative Biolabs has experts in data analysis and artificial intelligence and experts with extensive experience in cancer immunotherapy. Therefore, after successfully developing an efficient neoantigen prediction algorithm, we immediately developed its auxiliary platform - Neoantigen In Vitro Evaluation Platform - to evaluate and verify the predicted neoantigen. This platform consists of a T cell in vitro induction system, a humanized PDX mouse model evaluation system, and a cell-based MHC affinity evaluation system. It can reproduce the immune response triggered by natural processes in a laboratory environment and achieve more accurate identification of neoantigen as well as ensure the safety and effectiveness of tumor neoantigen.
Features of Neoantigen In Vitro Evaluation Platform
- Efficient complement of AI-aided tumor neoantigen prediction platform
- Comprehensive evaluation for safety and effectiveness of predicted neoantigens from molecule, cell and animal level
- Intuitive and accurate identification results
- Highly shortened evaluation cycle compared to traditional methods
- Improves the success rate of antigen identification, reduces treatment costs, and augments safety
- Greatly assists the development of individualized tumor neoantigen vaccine
The AI-aided analysis platform and neoantigen in vitro evaluation platform are two-horse carriage released by Creative Biolabs to develop personalized cancer vaccines. With bioinformatics and artificial intelligence experts, and with the research experience behind professional tumor vaccine developers, we have made gratifying progress in the development of personalized cancer neoantigen vaccines. These precious technologies and experience will greatly accelerate the success of cancer therapy.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
